Vetoquinol SA

Paris Stock Exchange VETO.PA

Vetoquinol SA Capital Expenditure for the year ending December 31, 2023: USD -20.98 M

Vetoquinol SA Capital Expenditure is USD -20.98 M for the year ending December 31, 2023, a 12.83% change year over year. Capital expenditure is cash spent on acquiring or maintaining fixed assets, such as property, plants, and equipment (PP&E).

Vetoquinol SA Capital Expenditure for the year ending December 31, 2022 was USD -24.07 M, a 34.74% change year over year.
Vetoquinol SA Capital Expenditure for the year ending December 31, 2021 was USD -36.89 M, a 79.24% change year over year.
Vetoquinol SA Capital Expenditure for the year ending December 31, 2020 was USD -177.69 M, a -1,576.24% change year over year.
Vetoquinol SA Capital Expenditure for the year ending December 31, 2019 was USD -10.60 M, a 17.86% change year over year.

Key data

Date	Capital Expenditure	Free Cash Flow	Depreciation And Amortization	Deferred Income Tax

Paris Stock Exchange: VETO.PA

Vetoquinol SA

CEO	Mr. Alain Masson
IPO Date	Nov. 17, 2006
Location	France
Headquarters	Magny-Vernois
Employees	2,519
Sector	Consumers Staples
Industries Pet Food Biotechnology Cleaning Supplies Cosmetics Drugstores & Retail Pharmacies Personal Care Pharmaceuticals Vaccines

Description

Vetoquinol SA, a veterinary pharmaceutical company, designs, develops, and sells veterinary drugs and non-medicinal products in Europe, the Americas, and the Asia Pacific region. It provides products in the areas of mobility, pain, and inflammation; dermatology, hygiene, and care; anti-parasite; udder health; infectious diseases; reproduction; behavior management; internal medicine; and cardiology-nephrology for cattle, sheep, pigs, poultry, and dogs. The company was founded in 1933 and is headquartered in Lure, France. Vetoquinol SA is a subsidiary of Soparfin SCA.

Key trends

Past 5 years